person · Reporting owner

BJERKHOLT ERIC

Disclosed activity across 9 companies

Tapewire entity: 24148
SEC CIK: 0001197350

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CERUS CORPCERS · Entity 5431	Director	June 09, 2026	June 12, 2026
CalciMedica, Inc.CALC · Entity 7804	Director	August 27, 2024	August 28, 2024
Metagenomi Therapeutics, Inc.MGX · Entity 7270	Director	June 09, 2026	June 11, 2026
Mirum Pharmaceuticals, Inc.MIRM · Entity 2416	CHIEF FINANCIAL OFFICER	September 11, 2026	September 15, 2026
Surrozen, Inc./DESRZN · Entity 6092	Director	May 13, 2026	May 14, 2026
Viracta Therapeutics, Inc.SNSS · Entity 85616	EVP, CFO & Corp. Secretary	November 30, 2016	December 06, 2016

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CERUS CORP

Report date June 09, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	261,679	Reported balance After 2026-06-09 transaction · row 1 1 source row Row 1 · 2026-06-09 · Sale · Disposed 20,454 · Balance 261,679

CalciMedica, Inc.

Report date August 27, 2024 · Filed August 28, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2034-08-26	Direct	10,000	Reported balance After 2024-08-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-08-27 · Grant · Acquired 10,000 · Balance 10,000 F1: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 28, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 28, 2024.

Metagenomi Therapeutics, Inc.

Report date June 09, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2036-06-08	Direct	21,000	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 21,000 · Balance 21,000 F1: The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date.

Mirum Pharmaceuticals, Inc.

Report date September 11, 2026 · Filed September 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	44,745	Ending reported balance After 2026-09-14 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-09-11 · Exercise / conversion · Acquired 18,333 · Balance 54,688 F1: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Row 2 · 2026-09-14 · Sale · Disposed 9,943 · Balance 44,745 F2: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-09-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-09-11 · Exercise / conversion · Disposed 18,333 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F3: The restricted stock units vest in a series of three successive equal annual installments beginning on the one-year anniversary of September 11, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).

F2: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

F3: The restricted stock units vest in a series of three successive equal annual installments beginning on the one-year anniversary of September 11, 2023.

Surrozen, Inc./DE

Report date May 13, 2026 · Filed May 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.14 · Expires 2036-05-12	Direct	5,550	Reported balance After 2026-05-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-13 · Grant · Acquired 5,550 · Balance 5,550 F1: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

Filing footnotes · ownership attribution and instrument terms

F1: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

Viracta Therapeutics, Inc.

Report date November 30, 2016 · Filed December 06, 2016 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2026-11-30	Direct	95,000	Reported balance After 2016-11-30 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2016-11-30 · Grant · Acquired 95,000 · Balance 95,000 F1: Twenty-five per cent (25%) of the total shares vest on November 30, 2017 and the remainder will vest ratably on each monthly anniversary thereafter such that the award will be fully vested on November 30, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: Twenty-five per cent (25%) of the total shares vest on November 30, 2017 and the remainder will vest ratably on each monthly anniversary thereafter such that the award will be fully vested on November 30, 2020.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Aimmune Therapeutics, Inc.

Report date October 10, 2020 · Filed October 14, 2020

Section 16 reporting ended · disclosed 2020-10-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, $0.0001 par valueSEC Table I · non-derivative	Direct	Reported balance After 2020-10-10 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2020-10-10 · Other · Disposed 27,805 · Balance 0 F1: Includes 1,869 shares acquired pursuant to the Issuer's employee stock purchase plan.
Common Stock, $0.0001 par valueSEC Table I · non-derivative	Direct	Reported balance After 2020-10-13 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2020-10-13 · Disposition to issuer · Disposed 23,905 · Balance 0 F2: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price"). F3: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.44	Direct	Reported balance After 2020-10-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-10-13 · Disposition to issuer · Disposed 264,800 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.07	Direct	Reported balance After 2020-10-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-10-13 · Disposition to issuer · Disposed 56,250 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.72	Direct	Reported balance After 2020-10-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-10-13 · Disposition to issuer · Disposed 78,750 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.81	Direct	Reported balance After 2020-10-13 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-10-13 · Disposition to issuer · Disposed 56,250 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 1,869 shares acquired pursuant to the Issuer's employee stock purchase plan.

F2: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price").

F3: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.

F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

CHINOOK THERAPEUTICS, INC.

Report date August 11, 2023 · Filed August 11, 2023

Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-08-11 transaction · row 1 1 source row Row 1 · 2023-08-11 · Disposition to issuer · Disposed 39,371 · Balance 0 F1: The number of shares reported includes 504 shares of the Issuer's Common Stock acquired, since that date of the reporting person's previous Form 4 filing, pursuant to the Issuer's employee stock purchase plan in transactions exempt from reporting under Rules 16b-3(c) and 16b-3(d). F2: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.98 · Expires 2030-11-29	Direct	Reported balance After 2023-08-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-08-11 · Disposition to issuer · Disposed 144,787 · Balance 0 F3: This stock option award, which provided for 25% of the award to vest on November 30, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.14 · Expires 2031-02-09	Direct	Reported balance After 2023-08-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-08-11 · Disposition to issuer · Disposed 21,501 · Balance 0 F4: This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.90 · Expires 2032-01-31	Direct	Reported balance After 2023-08-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-08-11 · Disposition to issuer · Disposed 88,000 · Balance 0 F5: This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.27 · Expires 2033-01-30	Direct	Reported balance After 2023-08-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-08-11 · Disposition to issuer · Disposed 84,000 · Balance 0 F6: This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-08-11 · Disposition to issuer · Disposed 16,415 · Balance 0 F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F8: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on November 30, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-08-11 · Disposition to issuer · Disposed 2,435 · Balance 0 F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F9: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-08-11 · Disposition to issuer · Disposed 14,667 · Balance 0 F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F10: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-08-11 · Disposition to issuer · Disposed 21,000 · Balance 0 F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F11: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-08-11 · Disposition to issuer · Disposed 8,400 · Balance 0 F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F12: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the performance-based RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

Filing footnotes · ownership attribution and instrument terms

F1: The number of shares reported includes 504 shares of the Issuer's Common Stock acquired, since that date of the reporting person's previous Form 4 filing, pursuant to the Issuer's employee stock purchase plan in transactions exempt from reporting under Rules 16b-3(c) and 16b-3(d).

F2: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.

F3: This stock option award, which provided for 25% of the award to vest on November 30, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F4: This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F5: This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F6: This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement.

F8: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on November 30, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

F9: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

F10: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

F11: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

F12: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the performance-based RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

Corium International, Inc.

Report date November 27, 2018 · Filed November 29, 2018

Section 16 reporting ended · disclosed 2018-11-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy The Bjerkholt Family Irrevocable Trust	Reported balance After 2018-11-27 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2018-11-27 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR").
Common StockSEC Table I · non-derivative	IndirectBy The Bjerkholt Children's Irrevocable Trust	Reported balance After 2018-11-27 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-11-27 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR").
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.97 · Expires 2025-04-13	Direct	Reported balance After 2018-11-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-11-27 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.19 · Expires 2025-12-17	Direct	Reported balance After 2018-11-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-11-27 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2026-12-21	Direct	Reported balance After 2018-11-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-11-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.59 · Expires 2027-11-30	Direct	Reported balance After 2018-11-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-11-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR").

F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 10, 2024 Filed May 16, 2024 20:30 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantCommon Stock	470	$21.05	$9,891.62	Disclosure SEC source: 0001415889-24-013356 · form4-05162024_040533.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,470 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 470 shares by the Reporting Person on May 10, 2024 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document
March 28, 2024 Filed Apr 23, 2024 01:51 UTC	CalciMedica, Inc. CALC · Entity 7804	GrantDirector Stock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $4.16	$0.00	Disclosure SEC source: 0001415889-24-011353 · form4-04232024_010410.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-03-27 F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant. Read SEC document
March 27, 2024 Filed Mar 28, 2024 00:47 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	PurchaseCommon Stock	2,000	$24.80	$49,600.00	Disclosure SEC source: 0001415889-24-009280 · form4-03282024_120312.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Read SEC document
March 18, 2024 Filed Mar 18, 2024 21:34 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	PurchaseCommon Stock	2,000	$25.80	$51,600.00	Disclosure SEC source: 0001415889-24-008311 · form4-03182024_090313.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Read SEC document
January 23, 2024 Filed Jan 26, 2024 00:10 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantRestricted Stock Units · Derivative	8,000	$0.00	$0.00	Disclosure SEC source: 0001415889-24-001824 · form4-01252024_070104.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document
January 23, 2024 Filed Jan 26, 2024 00:10 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantStock Option (right to buy) · Derivative	32,000	$0.00 Strike: $26.49	$0.00	Disclosure SEC source: 0001415889-24-001824 · form4-01252024_070104.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2034-01-22 F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document
December 13, 2023 Filed Dec 13, 2023 22:55 UTC	CERUS CORP CERS · Entity 5431	PurchaseCommon Stock	10,000	$1.62	$16,200.00	Disclosure SEC source: 0001209191-23-058544 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,133 Read SEC document
September 11, 2023 Filed Sep 12, 2023 22:23 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantRestricted Stock Units · Derivative	55,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-049133 · doc4.xml · derivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in a series of three successive equal annual installments beginning on the one year anniversary of September 11, 2023. F4 · derivative.expiration_date: The restricted stock units vest in a series of three successive equal annual installments beginning on the one year anniversary of September 11, 2023. Read SEC document
September 11, 2023 Filed Sep 12, 2023 22:23 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantStock Option (right to buy) · Derivative	110,000	$0.00 Strike: $30.43	$0.00	Disclosure SEC source: 0001209191-23-049133 · doc4.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2033-09-10 F2 · derivative.exercise_date: 1/4th of the shares subject to the Option will vest one year after September 11, 2023 (the "Vesting Commencement Date") and the balance of the shares will vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document
September 11, 2023 Filed Sep 12, 2023 22:23 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	PurchaseCommon Stock	10,000	$29.65	$296,492.00	Disclosure SEC source: 0001209191-23-049133 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported on this Form 4 is a weighted average price. The shares were purchased in multiple transactions ranging from $29.61 to $29.65, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth herein. Read SEC document
August 21, 2023 Filed Aug 23, 2023 22:08 UTC	CERUS CORP CERS · Entity 5431	PurchaseCommon Stock	10,000	$1.72	$17,151.00	Disclosure SEC source: 0001209191-23-047110 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,133 Read SEC document
August 11, 2023 Filed Aug 11, 2023 16:05 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Disposition to issuerRestricted Stock Units · Derivative	8,400	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-045414 · doc4.xml · derivative · entry 10 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,400 shares Expires not disclosed F7 · derivative.exercise_price: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F12 · price: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the performance-based RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F12 · derivative.exercise_date: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the performance-based RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F12 · derivative.expiration_date: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the performance-based RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. Read SEC document
August 11, 2023 Filed Aug 11, 2023 16:05 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Disposition to issuerRestricted Stock Units · Derivative	21,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-045414 · doc4.xml · derivative · entry 9 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,000 shares Expires not disclosed F7 · derivative.exercise_price: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F11 · price: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F11 · derivative.exercise_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F11 · derivative.expiration_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. Read SEC document
August 11, 2023 Filed Aug 11, 2023 16:05 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Disposition to issuerRestricted Stock Units · Derivative	14,667	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-045414 · doc4.xml · derivative · entry 8 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,667 shares Expires not disclosed F7 · derivative.exercise_price: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F10 · price: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F10 · derivative.exercise_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F10 · derivative.expiration_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. Read SEC document
August 11, 2023 Filed Aug 11, 2023 16:05 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Disposition to issuerRestricted Stock Units · Derivative	2,435	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-045414 · doc4.xml · derivative · entry 7 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,435 shares Expires not disclosed F7 · derivative.exercise_price: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F9 · price: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F9 · derivative.exercise_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F9 · derivative.expiration_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. Read SEC document
August 11, 2023 Filed Aug 11, 2023 16:05 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Disposition to issuerRestricted Stock Units · Derivative	16,415	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-045414 · doc4.xml · derivative · entry 6 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,415 shares Expires not disclosed F7 · derivative.exercise_price: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F8 · price: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on November 30, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F8 · derivative.exercise_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on November 30, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F8 · derivative.expiration_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on November 30, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. Read SEC document
August 11, 2023 Filed Aug 11, 2023 16:05 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Disposition to issuerStock Option (Right to Buy) · Derivative	84,000	$14.73 Strike: $25.27	$1,237,320.00	Disclosure SEC source: 0001209191-23-045414 · doc4.xml · derivative · entry 5 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 84,000 shares Expires 2033-01-30 F6 · derivative.exercise_date: This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document
August 11, 2023 Filed Aug 11, 2023 16:05 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Disposition to issuerStock Option (Right to Buy) · Derivative	88,000	$27.10 Strike: $12.90	$2,384,800.00	Disclosure SEC source: 0001209191-23-045414 · doc4.xml · derivative · entry 4 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 88,000 shares Expires 2032-01-31 F5 · derivative.exercise_date: This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document
August 11, 2023 Filed Aug 11, 2023 16:05 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Disposition to issuerStock Option (Right to Buy) · Derivative	21,501	$24.86 Strike: $15.14	$534,514.86	Disclosure SEC source: 0001209191-23-045414 · doc4.xml · derivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,501 shares Expires 2031-02-09 F4 · derivative.exercise_date: This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document
August 11, 2023 Filed Aug 11, 2023 16:05 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Disposition to issuerStock Option (Right to Buy) · Derivative	144,787	$26.02 Strike: $13.98	$3,767,357.74	Disclosure SEC source: 0001209191-23-045414 · doc4.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 144,787 shares Expires 2030-11-29 F3 · derivative.exercise_date: This stock option award, which provided for 25% of the award to vest on November 30, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document
August 11, 2023 Filed Aug 11, 2023 16:05 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Disposition to issuerCommon Stock	39,371	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-045414 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The number of shares reported includes 504 shares of the Issuer's Common Stock acquired, since that date of the reporting person's previous Form 4 filing, pursuant to the Issuer's employee stock purchase plan in transactions exempt from reporting under Rules 16b-3(c) and 16b-3(d). F2 · price: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:07 UTC	CERUS CORP CERS · Entity 5431	GrantCommon Stock	40,000	$5.00	$200,000.00	Disclosure SEC source: 0001209191-23-035749 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,133 F1 · shares: Represents the number of shares underlying RSUs. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document
May 31, 2023 Filed Jun 1, 2023 23:48 UTC	CalciMedica, Inc. CALC · Entity 7804	PurchaseCommon Stock	150	$4.20	$630.00	Disclosure SEC source: 0001209191-23-033460 · doc4.xml · nonDerivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,684 Read SEC document
May 31, 2023 Filed Jun 1, 2023 23:48 UTC	CalciMedica, Inc. CALC · Entity 7804	PurchaseCommon Stock	100	$4.09	$408.75	Disclosure SEC source: 0001209191-23-033460 · doc4.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,534 Read SEC document
May 30, 2023 Filed Jun 1, 2023 23:48 UTC	CalciMedica, Inc. CALC · Entity 7804	PurchaseCommon Stock	5	$3.25	$16.25	Disclosure SEC source: 0001209191-23-033460 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,434 Read SEC document
May 23, 2023 Filed May 23, 2023 21:57 UTC	CERUS CORP CERS · Entity 5431	PurchaseCommon Stock	5,000	$2.00	$10,000.00	Disclosure SEC source: 0001209191-23-031710 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,133 Read SEC document
May 23, 2023 Filed May 25, 2023 00:16 UTC	CalciMedica, Inc. CALC · Entity 7804	PurchaseCommon Stock	500	$3.27	$1,634.00	Disclosure SEC source: 0001209191-23-032025 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,429 Read SEC document
May 19, 2023 Filed May 22, 2023 20:32 UTC	CalciMedica, Inc. CALC · Entity 7804	PurchaseCommon Stock	199	$2.65	$527.35	Disclosure SEC source: 0001209191-23-031472 · doc4.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,929 Read SEC document
May 18, 2023 Filed May 18, 2023 22:08 UTC	CalciMedica, Inc. CALC · Entity 7804	PurchaseCommon Stock	300	$2.70	$810.00	Disclosure SEC source: 0001209191-23-030782 · doc4.xml · nonDerivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,729 Read SEC document
May 18, 2023 Filed May 19, 2023 20:09 UTC	Surrozen, Inc./DE SRZN · Entity 6092	GrantOption (right to buy) · Derivative	20,000	$0.00 Strike: $0.56	$0.00	Disclosure SEC source: 0001593968-23-000837 · primary_01.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-05-18 Read SEC document
May 18, 2023 Filed May 22, 2023 20:32 UTC	CalciMedica, Inc. CALC · Entity 7804	PurchaseCommon Stock	1	$2.65	$2.65	Disclosure SEC source: 0001209191-23-031472 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,730 Read SEC document
May 17, 2023 Filed May 18, 2023 22:08 UTC	CalciMedica, Inc. CALC · Entity 7804	PurchaseCommon Stock	200	$2.67	$534.00	Disclosure SEC source: 0001209191-23-030782 · doc4.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,429 Read SEC document
May 16, 2023 Filed May 18, 2023 22:08 UTC	CalciMedica, Inc. CALC · Entity 7804	PurchaseCommon Stock	800	$2.70	$2,160.00	Disclosure SEC source: 0001209191-23-030782 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,229 F1 · price: The weighted average purchase price for the transaction reported was $2.70, and the range of prices were between $2.605 and $2.76. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document
May 08, 2023 Filed Jun 28, 2023 23:49 UTC	CalciMedica, Inc. CALC · Entity 7804	GrantDirector Stock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $3.25	$0.00	Disclosure SEC source: 0001209191-23-040095 · doc4.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-05-07 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest in equal monthly installments over a three year period following the date of grant. Read SEC document
March 23, 2023 Filed Mar 27, 2023 23:55 UTC	CalciMedica, Inc. GRAY · Entity 7804	Disposition to issuerRestricted Stock Unit · Derivative	1,429	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-021298 · doc4.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,429 shares Expires not disclosed F1 · derivative.exercise_price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Eric Bjerkholt's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. F1 · price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Eric Bjerkholt's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. F1 · derivative.exercise_date: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Eric Bjerkholt's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. F1 · derivative.expiration_date: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Eric Bjerkholt's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. Read SEC document
March 23, 2023 Filed Mar 27, 2023 23:55 UTC	CalciMedica, Inc. GRAY · Entity 7804	Disposition to issuerCommon Stock	1,429	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-021298 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,429 F1 · price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Eric Bjerkholt's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023. Read SEC document
February 10, 2023 Filed Feb 15, 2023 16:41 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionRestricted Stock Units · Derivative	2,435	$0.00	$0.00	Disclosure SEC source: 0001209191-23-009776 · doc4.xml · derivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,435 Underlying: Common Stock · 2,435 shares Expires 2024-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document
February 10, 2023 Filed Feb 15, 2023 16:41 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	SaleCommon Stock	857	$23.75	$20,352.46	Disclosure SEC source: 0001209191-23-009776 · doc4.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,867 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document
February 10, 2023 Filed Feb 15, 2023 16:41 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionCommon Stock	2,435	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-009776 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document
January 31, 2023 Filed Feb 2, 2023 18:14 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantRestricted Stock Unit · Derivative	21,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-006373 · doc4.xml · derivative · entry 5 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2024, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. F6 · derivative.expiration_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2024, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document
January 31, 2023 Filed Feb 2, 2023 18:14 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantStock Option (Right to Buy) · Derivative	84,000	$0.00 Strike: $25.27	$0.00	Disclosure SEC source: 0001209191-23-006373 · doc4.xml · derivative · entry 4 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,000 Underlying: Common Stock · 84,000 shares Expires 2033-01-30 F5 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 31, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
January 31, 2023 Filed Feb 2, 2023 18:14 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionRestricted Stock Unirt · Derivative	7,333	$0.00	$0.00	Disclosure SEC source: 0001209191-23-006373 · doc4.xml · derivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,667 Underlying: Common Stock · 7,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document
January 31, 2023 Filed Feb 2, 2023 18:14 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	SaleCommon Stock	2,891	$24.68	$71,356.53	Disclosure SEC source: 0001209191-23-006373 · doc4.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,289 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document
January 31, 2023 Filed Feb 2, 2023 18:14 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionCommon Stock	7,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-006373 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document
December 01, 2022 Filed Dec 2, 2022 16:25 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	SaleCommon Stock	5,770	$22.29	$128,601.76	Disclosure SEC source: 0001209191-22-059415 · doc4.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,847 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document
November 30, 2022 Filed Dec 2, 2022 16:25 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionRestricted Stock Units · Derivative	16,414	$0.00	$0.00	Disclosure SEC source: 0001209191-22-059415 · doc4.xml · derivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,415 Underlying: Common Stock · 16,414 shares Expires 2023-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The RSUs vested as to 33.33% of the total shares on November 30, 2021 and November 30, 2022, and thereafter vests as to 33.33% of the total RSUs on November 30, 2023, subject to the provision of services to the Company on each vesting date. Read SEC document
November 30, 2022 Filed Dec 2, 2022 16:25 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionCommon Stock	16,414	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-059415 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSU") convert into common stock on a one-for-one basis. Read SEC document
June 02, 2022 Filed Jun 3, 2022 21:32 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantRestricted Stock Units · Derivative	20,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034252 · doc4.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's Common Stock, subject to the reporting person's continued status as a service provider to the issuer. F1 · derivative.exercise_date: The award vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2023 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. F3 · derivative.expiration_date: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date. Read SEC document
June 02, 2022 Filed Jun 3, 2022 21:32 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $0.98	$0.00	Disclosure SEC source: 0001209191-22-034252 · doc4.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: The award vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2023 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document
June 01, 2022 Filed Jun 3, 2022 21:08 UTC	CERUS CORP CERS · Entity 5431	GrantOption (Right to Buy) · Derivative	39,866	Not disclosed Strike: $4.84	Not disclosed	Disclosure SEC source: 0001209191-22-034203 · doc4.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,866 Underlying: Common Stock · 39,866 shares Expires 2032-05-31 F3 · price: Not applicable. F2 · derivative.exercise_date: The option shall vest one year from the date of grant. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.